# Nusano, Inc.
Nusano, Inc. is an American radioisotope production company that describes itself as a "physics company" and builds a patented ion-source and linear-accelerator platform to make medical and industrial radioisotopes.[2](https://nusano.com/series-c/) • [3](https://nusano.com/technology/) It is organized as a Delaware corporation under CIK 0001721322, and its 2022 Form D lists its address at 28575 Livingston Ave., Valencia, California, while its production platform is in [West Valley City](https://www.edgepedia.org/west-valley-city), Utah.[1](https://www.sec.gov/Archives/edgar/data/1721322/000172132222000002/0001721322-22-000002-index.htm) • [2](https://nusano.com/series-c/) The company remained active through its last recorded announcements in October 2025.[5](https://o.parsers.vc/startup/nusano.com/)
| Key fact | Detail |
|---|---|
| Legal entity | Nusano, Inc., Delaware corporation, CIK 0001721322[1](https://www.sec.gov/Archives/edgar/data/1721322/000172132222000002/0001721322-22-000002-index.htm) |
| Locations | Valencia, California address on 2022 Form D; production platform in West Valley City, Utah[1](https://www.sec.gov/Archives/edgar/data/1721322/000172132222000002/0001721322-22-000002-index.htm) • [2](https://nusano.com/series-c/) |
| Sector | Radioisotope production for medical and industrial uses[2](https://nusano.com/series-c/) |
| Capital raised | ~$102.65 million sold across Form D offerings 2017–2022; over $115 million Series C announced October 2024[1](https://www.sec.gov/Archives/edgar/data/1721322/000172132222000002/0001721322-22-000002-index.htm) • [2](https://nusano.com/series-c/) |
| Investors | Wasatch Group (lead, Series C), S32; previous investors Verily and the American Cancer Society's BrightEdge[2](https://nusano.com/series-c/) |
| Lead products | Non-carrier-added lutetium-177 and actinium-225, plus copper, astatine, iridium, and scandium isotopes[2](https://nusano.com/series-c/) |
| Status | Company announcements continue through October 2025[5](https://o.parsers.vc/startup/nusano.com/) |
## Technology
The core machine is an ion source feeding a linear accelerator. Nusano says its patented ion source generates heavy ions (He++ and 2H+) on a scale orders of magnitude greater than existing comparable sources, producing beams that include alpha, deuterium, helion, lithium, and carbon.[3](https://nusano.com/technology/) A series of magnets directs the particles to one of 12 targets at the end of the beam line; when they collide with the target material, a radioisotope is created.[3](https://nusano.com/technology/)
Per the company, the platform can produce up to 12 different radioisotopes simultaneously and switch targets quickly to create more than 40 different isotopes.[3](https://nusano.com/technology/) Nusano also states that its proprietary separation processes enable high-volume, high-purity (cGMP) isotope production, and that it runs a stable isotope program aimed at reducing dependence on foreign supply chains.[3](https://nusano.com/technology/) These figures are company claims; no independent verification of the machine's throughput was retrieved.
## Funding
Nusano's SEC record shows a series of Form D exempt equity offerings from 2017 through November 2022 in which approximately $102.65 million in total was sold; the final round, dated November 1, 2022, reported $15,364,583 sold against a $10 million offering amount.[1](https://www.sec.gov/Archives/edgar/data/1721322/000172132222000002/0001721322-22-000002-index.htm) On October 1, 2024, the company announced a Series C financing with funding commitments of over $115 million in total proceeds, led by The Wasatch Group with participation by S32; previous investors include Verily and the [American Cancer Society](https://www.edgepedia.org/american-cancer-society)'s BrightEdge.[2](https://nusano.com/series-c/) An aggregator directory reports roughly $125 million raised across rounds, a figure that conflicts with the filings and the announced Series C and is unverified.[5](https://o.parsers.vc/startup/nusano.com/)
## Business and traction
The Series C funds initial product launches of non-carrier-added lutetium-177, which had been scheduled to begin in Q1 2025, and actinium-225; both are therapeutic isotopes used in radiopharmaceutical development.[2](https://nusano.com/series-c/) CEO Chris Lowe said the financing supports stabilizing radiopharmaceutical supply chains and that new radioisotope supplies would come online starting in 2025, including astatine, copper, iridium, and scandium.[2](https://nusano.com/series-c/)
According to its releases, Nusano's production platform opening in 2025 in West Valley City, Utah will support Ac-225 production and be capable of generating more than 25 radioisotopes for medical and industrial uses.[2](https://nusano.com/series-c/) Aggregator-carried headlines (unverified) report a commercial-scale copper-64 supply agreement with Clarity Pharmaceuticals (ASX: CU6) announced April 17, 2025, which references a 190,000 square foot Nusano facility in West Valley City, and a copper-67 supply agreement with Clarity announced October 16, 2025.[5](https://o.parsers.vc/startup/nusano.com/)
## Recent developments
Three developments mark the post-2023 record, all from company announcements. The October 2024 Series C of over $115 million shifted Nusano from filing-stage fundraising toward commercialization.[2](https://nusano.com/series-c/) In 2025 the company said it would launch its Lu-177 separation process and the Utah production platform.[2](https://nusano.com/series-c/) On June 12, 2025, Nusano announced a High-Assay Low-Enriched Uranium (HALEU) nuclear-fuel program, claiming to be the first private US company to offer a scalable commercial HALEU solution; it intends to produce initial commercial samples by Q4 2026, begin large-scale production in Q1 2027, with a single system producing more than 50 metric tons annually and scale to approximately 350 metric tons annually by 2029.[4](https://www.globenewswire.com/news-release/2025/06/12/3098023/0/en/Nusano-Announces-Breakthrough-HALEU-Program-Expected-to-Produce-Up-to-350-Metric-Tons-of-Fuel-Annually-for-Advanced-Nuclear-Reactors.html) The HALEU program is a diversification from medical isotopes into advanced-reactor fuel, and its timelines rest on company projections alone.
## References
1. [EDGAR Form D, Nusano, Inc. (0001721322-22-000002)](https://www.sec.gov/Archives/edgar/data/1721322/000172132222000002/0001721322-22-000002-index.htm)
2. [Nusano Announces Series C Financing of Over $115M to Commercialize Radioisotopes (Nusano press release)](https://nusano.com/series-c/)
3. [Technology – Nusano (company page)](https://nusano.com/technology/)
4. [Nusano Announces Breakthrough HALEU Program (GlobeNewswire, June 12, 2025)](https://www.globenewswire.com/news-release/2025/06/12/3098023/0/en/Nusano-Announces-Breakthrough-HALEU-Program-Expected-to-Produce-Up-to-350-Metric-Tons-of-Fuel-Annually-for-Advanced-Nuclear-Reactors.html)
5. [Nusano – Funding, Valuation, Investors, News (aggregator, unverified items)](https://o.parsers.vc/startup/nusano.com/)
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups › Contract development and manufacturing organizations*
*Initially written Sep 17, 2026 · Reviewed: Sep 19, 2026 · Edited: Sep 19, 2026; Oct 11, 2026; Oct 15, 2026 · Last review: Sep 19, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license